These conclusions coincide with the ones generated by our tool in that overall IGlar is superior to NPH insulin, in particular with respect to safety and in reducing the risk of nocturnal hypoglycemia, but not superior in efficacy in terms of the reduction of HbA1c levels. Here, INS is linked to Hypoglycemia.